Method of improving cerebral function

Abstract

Disclosed in certain embodiments is a pharmaceutical composition comprising a sugar; a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.

1 - 35 . (canceled)  
   
   
       36 . A method of improving cerebral function comprising administering to a patient in need thereof a pharmaceutical composition comprising: 
 a sugar;    a Krebs cycle intermediate, precursor of a Krebs cycle intermediate, salt thereof, or combination thereof; and    a component selected from the group consisting of an unsaturated lipid, phenylethylamine, a soluble calcium compound, or a combination thereof.    
   
   
       37 . The method of  claim 36 , wherein the pharmaceutical composition is in the form of an edible solid or liquid.  
   
   
       38 . The method of  claim 37 , wherein the edible solid is in the form of a confectionary product.  
   
   
       39 . The method of  claim 37 , wherein the edible liquid comprises a fruit juice.  
   
   
       40 . The method of  claim 36 , wherein the pharmaceutical formulation is in the form of chewable or edible bars, confectionary products, cookies, baked or simulated baked goods, biscuits, lozenges, juice drinks or chewing gum.  
   
   
       41 . (canceled)  
   
   
       42 . The method of  claim 36 , wherein the pharmaceutical composition is in the form of an oral solid dosage form, a parenteral product, an intramucosal product or a suppository.  
   
   
       43 . The method of  claim 36 , wherein the unsaturated lipid in the pharmaceutical composition is selected from the group consisting of unsaturated monoglycerides, unsaturated diglycerides, unsaturated triglycerides, unsaturated fatty acids, unsaturated fatty alcohols, unsaturated phosphatides, unsaturated sterols, unsaturated fat-soluble vitamins, unsaturated terpenes, and mixtures thereof.  
   
   
       44 . The method of  claim 36 , wherein the unsaturated lipid in the pharmaceutical composition is selected from the group consisting of high oleic sunflower oil, sunflower oil, rapeseed oil, soybean oil, peanut oil, canola oil, cottonseed oil, coconut oil, palm oil, palm kernel oil, corn oil, flax seed oil, olive oil, safflower oil, fish oil, and mixtures thereof.  
   
   
       45 . The method of  claim 36 , wherein the unsaturated lipid in the pharmaceutical composition is selected from the group consisting of flax seed oil, fish oil, and mixtures thereof.  
   
   
       46 . The method of  claim 36 , wherein the phenylethylamine in the pharmaceutical composition is phenylethyl-2-amine.  
   
   
       47 . The method of  claim 36 , wherein the soluble calcium compound in the pharmaceutical composition is selected from the group consisting of calcium lactate, calcium sulfate, calcium citrate, calcium malate, calcium gluconate and combinations thereof.  
   
   
       48 . The method of  claim 47 , wherein the soluble calcium compound in the pharmaceutical composition is calcium malate.  
   
   
       49 . The method of  claim 36 , wherein the Krebs cycle intermediate in the pharmaceutical composition is selected from a group consisting of citric acid, aconitic acid, isocitric acid, a-ketoglutaric, succinic acid, fumaric acid, malic acid, oxaloacetic acid, and combinations thereof.  
   
   
       50 . The method of  claim 36 , wherein the precursor in the pharmaceutical composition is selected from a group consisting of 2-keto-4-hydroxypropanol, 2,4-dihydroxybutanol, 2-keto-4-hydroxybutanol, 2,4-dihydroxybutyric acid, 2-keto-4-hydroxybutyric acid, aspartate, mono-alkyl esters of oxaloacetate, di-alkyl esters of oxaloacetate, and mixtures thereof.  
   
   
       51 . The method of  claim 36 , wherein the sugar in the pharmaceutical composition is selected from the group consisting of a monosaccharide, disaccharide, polysaccharide, and mixtures thereof.  
   
   
       52 . The method of  claim 51 , wherein the monosaccharide is selected from a group consisting of glucose, fructose, mannose, galactose, and mixtures thereof.  
   
   
       53 . The method of  claim 51 , wherein the disaccharide is selected from a group consisting of sucrose, maltose, lactose, and mixtures thereof.  
   
   
       54 . The method of  claim 51 , wherein the polysaccharide is a starch.  
   
   
       55 . The method of  claim 36 , wherein the pharmaceutical composition further comprises a mitochondrial function enhancing compound.  
   
   
       56 . The method of  claim 55 , wherein the mitochondrial function enhancing compound is selected from the group consisting of a vitamin, a mineral, an antioxidant, a metabolism-enhancing compound, and mixtures thereof.  
   
   
       57 . The method of  claim 56 , wherein the metabolism-enhancing compound is selected from the group consisting of creatine, L-carnitine, L-carnitine derivatives, and mixtures thereof.  
   
   
       58 . The method of  claim 56 , wherein the vitamin is selected from the group consisting of thiamin, riboflavin, niacin, pyridoxine derivatives, pantothenic acid, and mixtures thereof.  
   
   
       59 . The method of  claim 56 , wherein the mineral is selected from the group consisting of calcium, magnesium, sodium, potassium, zinc, and mixtures thereof.  
   
   
       60 . The method of  claim 56 , wherein the antioxidant is selected from the group consisting of ascorbic acid, alpha-tocopherol, resveritrol, quercetin, and mixtures thereof.  
   
   
       61 . The method of  claim 36 , wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable excipient.